Graphene oxide (GO) modified with hyaluronic acid (HA) and Arg-gly-asp peptide (RGD) was designed as a dual-receptor targeting drug delivery system to enhance the specificity and efficiency of anticancer drug delivery. Firstly, GO-HA-RGD conjugate was characterized to reveal its structure and morphology. Whereafter, doxorubicin (Dox) as a model drug was loaded on GO-HA-RGD carrier, which displayed a high loading rate (72.9%, GO:Dox (w/w) = 1:1), pH-response and sustained drug release behavior. Cytotoxicity experiments showed that GO-HA-RGD possessed excellent biocompatibility towards SKOV-3 and HOSEpiC cells. Additionally, the GO-HA-RGD/Dox had a stronger cytotoxicity for SKOV-3 cells than either GO-HA/Dox (single receptor) or GO/Dox (no receptor). Moreover, celluar uptake studies illustrated that GO-HA-RGD conjugate could be effectively taken up by SKOV-3 cells via a synergic effect of CD44-HA and integrin-RGD mediated endocytosis. Hence, GO-HA-RGD nanocarrier is able to be a promising platform for targeted cancer therapeutic.
ErttmannRErbNSteinhoffA. Pharmacokinetics of Doxorubicin in man dose and schedule dependence. J Cancer Res Clin Oncol1988; 114: 509–513.
2.
SlamonDJLeyland-JonesBShakS. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl Jo Med2001; 344: 783–792.
3.
ChoHJYoonISYoonHY. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials2012; 33: 1190–1200.
4.
HuangPBaoLZhangC. Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy. Biomaterials2011; 32: 9796–9809.
5.
JiangTZhangZZhangY. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials2012; 33: 9246–9258.
6.
WenHYDongHQXieWJ. Rapidly disassembling nanomicelles with disulfide-linked PEG shells for glutathione-mediated intracellular drug delivery. Chem Commun2011; 47: 3550–3352.
7.
OrecchioniMCabizzaRBiancoA. Graphene as cancer theranostic tool: progress and future challenges. Theranostics2015; 5: 710–723.
8.
ChenYSYangXYZhangZY. High efficiency loading and controlled release of doxorubicin hydro-chloride on graphene oxide. J Phys Chem C2008; 112: 17554–17558.
9.
ZhuYMuraliSCaiW. Graphene and graphene oxide: synthesis, properties, and applications. Adv Mater2010; 22: 3906–3924.
10.
JungHSKongWHSungDK. Nanographene oxide-hyaluronic acid conjugate for photothermal ablation therapy of skin cancer. Acsnano2014; 8: 260–268.
ChoiHYLeeTJYangGM. Efficient mRNA delivery with graphene oxide-polyethylenimine for generation of footprint-free human induced pluripotent stem cells. J Controll Release2016; 235: 222–235.
13.
LuCHYangHHZhuCL. A graphene platform for sensing biomolecules. Angew Chem2009; 48: 4785–4797.
14.
YangXWangYHuangX. Multi-functionalized graphene oxide based anticancer drug-carrier with dual-targeting function and pH-sensitivity. J Mater Chem2011; 21: 3448–3454.
15.
SongEHanWLiC. Hyaluronic acid-decorated graphene oxide nanohybrids as nanocarriers for targeted and pH-responsive anticancer drug delivery. ACS Appl Mater Interf2014; 6: 11882–11890.
16.
YangHWLuYJLinKJ. EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy. Biomaterials2013; 34: 7204–7214.
17.
ZhangLXiaJZhaoQ. Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs. Small2010; 6: 537–544.
18.
LiJHuoMWangJ. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials2012; 33: 2310–2320.
19.
SeguraTAndersonBCChungPH. Crosslinked hyaluronic acid hydrogels: a strategy to functionalize and pattern. Biomaterials2005; 26: 359–371.
20.
XuHZhangLBaoY. Preparation and characterization of injectable chitosan–hyaluronic acid hydrogels for nerve growth factor sustained release. J Bioactive Compat Polym2016; 32: 1–17.
21.
JungHSLeeMYKongWH. Nano graphene oxide–hyaluronic acid conjugate for target specific cancer drug delivery. RSC Adv2014; 4: 14197–14200.
22.
MiaoWShimGKangCM. Cholesteryl hyaluronic acid-coated, reduced graphene oxide nanosheets for anti-cancer drug delivery. Biomaterials2013; 34: 9638–9647.
23.
YangHBremnerDHTaoL. Carboxymethyl chitosan-mediated synthesis of hyaluronic acid-targeted graphene oxide for cancer drug delivery. Carbohyd Polym2016; 135: 72–78.
24.
OuastiSKinghamPJTerenghiG. The CD44/integrins interplay and the significance of receptor binding and re-presentation in the uptake of RGD-functionalized hyaluronic acid. Biomaterials2012; 33: 1120–1134.
25.
AguiarDJKnudsonWKnudsonCB. Internalization of the hyaluronan receptor CD44 by chondrocytes. Exp Cell Res1999; 252: 292–302.
26.
GlassRJDickersonKTStecckerK. Characterization of a hyaluronic acid-Arg-Gly-Asp peptide cell attachment matrix. Biomaterials1996; 17: 1101–1108.
XiongXBHuangYLuWL. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Controll Release2005; 107: 262–275.
29.
GarangerEBoturynDDumyP. Tumor targeting with RGD Peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anti Cancer Agents Med Chem2007; 7: 552–558.
30.
MikelisCSfaelouEKoutsioumpaM. Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta. FASEB J2009; 23: 1459–1469.
31.
WangJHanXYangH. A novel RGD-toxin protein, Lj-RGD3, from the buccal gland secretion of Lampetra japonica impacts diverse biological activities. Biochimie2010; 92: 1387–1396.
32.
Lamberti G, Kiani MF and Wang B. Improving the binding efficiency of a vascular drug delivery system by using a dual-receptor targeting strategy. America: Bioeng Conf IEEE, 2012, pp.131–132.
33.
BhattacharyyaSKhanJACurranGL. Efficient delivery of gold nanoparticles by dual receptor targeting. Adv Mater2011; 23: 5034–5038.
34.
LiuYSunJCaoW. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm2011; 421: 160–169.
35.
LeeJYTermsarasabUParkJH. Dual CD44 and folate receptor-targeted nanoparticles for cancer diagnosis and anticancer drug delivery. J Controll Release2016; 236: 38–46.
36.
TianHLinLChenJ. RGD targeting hyaluronic acid coating system for PEI-PBLG polycation gene carriers. J Controll Release2011; 155: 47–53.
37.
XuHWangZLiY. Preparation and characterization of a dual-receptor mesoporous silica nanoparticle-hyaluronic acid-RGD peptide targeting drug delivery system. RSC Adv2016; 6: 40427–40435.
38.
MarcanoDCKosynkinDVBerlinJM. Improved Synthesis of Graphene Oxide. Acsnano2010; 4: 4806–4814.
39.
PouyaniTPrestwichGD. Functionalized derivatives of Hyaluronic acid oligosaccharides: drug carriers and novel biomaterials. Bioconjuate Chem1994; 5: 339–347.
40.
HuangJZongCShenH. Mechanism of cellular uptake of graphene oxide studied by surface-enhanced Raman spectroscopy. Small2012; 8: 2577–2584.
41.
MuQSuGLiL. Size-dependent cell uptake of protein-coated graphene oxide nanosheets. ACS Appl Mater Interf2012; 4: 2259–2266.
42.
ThorneRFLeggJWIsackeCM. The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. Commentary2004; 117: 373–380.
43.
LammelTBoisseauxPFernándezcruzML. Internalization and cytotoxicity of graphene oxide and carboxyl graphene nanoplatelets in the human hepatocellular carcinoma cell line Hep G2. Particle Fibre Toxicol2013; 10: 27–48.
44.
DorfmanA. The in vitro action of hyaluronidase. Ann N Y Acad Sci2006; 25: 1017–1020.
45.
ChoiKYYoonHYKimJH. Smart nanocarrier based on pegylated hyaluronic acid for cancer therapy. Acsnano2011; 5: 8591–8599.
46.
CultyMNguyenHUnderhillC. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol1992; 116: 8591–8599.
47.
KrishnamooyrhyKVeerapandianMYunK. The chemical and structural analysis of graphene oxide with different degrees of oxidation. Carbon2013; 53: 38–49.
48.
LiuKZhangJJChengFF. Green and facile synthesis of highly biocompatible graphene nanosheets and its application for cellular imaging and drug delivery. J Mater Chem2011; 21: 12034–12040.
49.
ShiJMaRWangL. The application of hyaluronic acid-derivatized carbon nanotubes in hematoporphyrin monomethyl ether-based photodynamic therapy for in vivo and in vitro cancer treatment. Int J Nanomed2013; 8: 2361–2373.
50.
WuHShiHWangY. Hyaluronic acid conjugated graphene oxide for targeted drug delivery. Carbon2014; 69: 379–389.
51.
LiFParkSJLingD. Hyaluronic acid-conjugated graphene oxide/photosensitizer nanohybrids for cancer targeted photodynamic therapy. J Mater Chem B2013; 1: 1678–1686.
52.
BaoHPanYPingY. Chitosan-functionalized graphene oxide as a nanocarrier for drug and gene delivery. Small2011; 7: 1569–1578.
53.
WenHDongCDongH. Engineered redox-responsive PEG detachment mechanism in PEGylated nano-graphene oxide for intracellular drug delivery. Small2012; 8: 760–769.
54.
KimHLeeDKimJ. Photothermally triggered cytosolic drug delivery via endosome disruption using a functionalized reduced graphene oxide. Int J Nanomed2013; 8: 2361–2373.
55.
KavithaTAbdiSIParkSY. pH-sensitive nanocargo based on smart polymer functionalized graphene oxide for site-specific drug delivery. Phys Chem Chem Phys2013; 15: 5176–5185.
56.
LiuZRobinsonJTSunX. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc2008; 130: 10876–10877.
57.
HsiehAGKorkutSPuncktC. Dispersion stability of functionalized graphene in aqueous sodium dodecyl sulfate solutions. Langmuir2013; 29: 14831–14838.
58.
BordonKCPerinoMGGiglioJR. Isolation, enzymatic characterization and antiedematogenic activity of the first reported rattlesnake hyaluronidase from Crotalus durissus terrificus venom. Biochimie2012; 94: 2740–2748.
